LOGC:NSD-Contextlogic Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 6.78

Change

+0.04 (+0.59)%

Market Cap

N/A

Volume

0.36M

Analyst Target

USD 22.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-11.58 (-2.37%)

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

-1.67 (-0.30%)

USD 69.68B
ARGX argenx NV ADR

-0.50 (-0.08%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

-1.81 (-0.77%)

USD 30.51B
ONC BeiGene, Ltd.

-1.76 (-0.76%)

USD 26.35B
RPRX Royalty Pharma Plc

-0.41 (-1.26%)

USD 19.31B
SMMT Summit Therapeutics PLC

+0.61 (+2.48%)

USD 14.57B
INSM Insmed Inc

-3.14 (-4.32%)

USD 12.52B
INCY Incyte Corporation

-1.41 (-2.42%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

-0.52 (-0.88%)

USD 11.50B

ETFs Containing LOGC

INKM SPDR® SSgA Income Alloca.. 14.30 % 0.39 %

-0.30 (-1.50%)

USD 0.07B
TACK Fairlead Tactical Sector .. 4.37 % 0.00 %

-0.39 (-1.50%)

USD 0.21B
FISR SPDR® SSGA Fixed Income .. 0.00 % 0.00 %

-0.18 (-1.50%)

USD 0.35B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.56% 77% C+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.56% 77% C+ 67% D+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -95.94% 23% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.94% 23% F 7% C-
Average Annual (5 Year Horizon)  
Capital Gain 63.88% 83% B 91% A-
Dividend Return 63.88% 83% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 167.44% 25% F 13% F
Risk Adjusted Return 38.15% 90% A- 71% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.